BioNTech (22UA.F) stock price, revenue, and financials

BioNTech market cap is €24.4 b, and annual revenue was €1.99 m in FY 2019

€24.4 B

22UA.F Mkt cap, 08-Jan-2021

€2 M

BioNTech Revenue FY, 2019
BioNTech Gross profit (FY, 2019)-15.4 M
BioNTech Gross profit margin (FY, 2019), %(774.6%)
BioNTech Net income (FY, 2019)-179.2 M
BioNTech EBIT (FY, 2019)-181.5 M
BioNTech Cash, 31-Dec-2019519.1 M

BioNTech Revenue

BioNTech revenue was €1.99 m in FY, 2019

Embed Graph

BioNTech Revenue Breakdown

Embed Graph

BioNTech revenue breakdown by business segment: 20.2% from Other Sales Transactions and 79.8% from Collaboration Revenue

BioNTech Income Statement

Annual

EURFY, 2017FY, 2018FY, 2019

Revenue

61.6m127.6m2.0m

Revenue growth, %

107%

Cost of goods sold

9.3m13.7m17.4m

Gross profit

52.3m113.9m(15.4m)

Gross profit Margin, %

85%89%(775%)

Sales and marketing expense

6.6m3.0m

R&D expense

85.5m143.0m

Operating expense total

92.4m146.8m272.7m

EBIT

(181.5m)

EBIT margin, %

(9144%)

Interest income

2.1m2.0m

Pre tax profit

(85.9m)(47.7m)(179.4m)

Income tax expense

45.0k600.0k(268.0k)

Net Income

(85.9m)(48.3m)(179.2m)

BioNTech Balance Sheet

Annual

EURFY, 2017FY, 2018FY, 2019

Cash

172.1m411.5m519.1m

Accounts Receivable

4.6m18.9m11.9m

Inventories

11.7m

Current Assets

172.1m449.0m560.2m

PP&E

101.5m116.0m93.0m

Goodwill

89.4m

Total Assets

374.7m653.0m797.6m

Accounts Payable

52.5m71.7m

Short-term debt

1.8m2.1m

Current Liabilities

158.5m126.1m138.1m

Long-term debt

50.3m54.2m

Non-Current Liabilities

166.0m

Total Debt

52.2m56.4m

Total Liabilities

422.9m386.0m304.2m

Common Stock

166.8m193.3m

Retained Earnings

(197.8m)(245.8m)

Total Equity

(48.2m)267.0m493.5m

Debt to Equity Ratio

-1.1 x0.2 x

Debt to Assets Ratio

0.1 x0.1 x

Financial Leverage

-7.8 x2.4 x1.6 x

Quarterly

EURQ2, 2019

Cash

284.9m

Accounts Receivable

8.9m

Current Assets

504.3m

PP&E

123.1m

Total Assets

722.4m

Accounts Payable

16.9m

Short-term debt

3.0m

Current Liabilities

136.0m

Long-term debt

61.3m

Total Debt

64.4m

Total Liabilities

337.9m

Common Stock

212.7m

Retained Earnings

(336.5m)

Total Equity

384.5m

Financial Leverage

1.9 x

BioNTech Cash Flow

Annual

EURFY, 2017FY, 2018FY, 2019

Net Income

(85.9m)(48.3m)(179.2m)

Depreciation and Amortization

10.5m22.0m33.9m

Inventories

(574.0k)(1.3m)

Cash From Operating Activities

(4.6m)(58.2m)(198.5m)

Purchases of PP&E

(24.3m)(30.6m)

Cash From Investing Activities

(52.5m)(67.1m)(77.1m)

Long-term Borrowings

(1.6m)(2.1m)

Cash From Financing Activities

(1.6m)365.2m383.3m

Net Change in Cash

(106.8m)239.8m107.6m

Interest Paid

(729.0k)(1.8m)

Income Taxes Paid

(45.0k)(304.0k)

Quarterly

EURQ2, 2018Q2, 2019

Net Income

(23.3m)(90.8m)

Depreciation and Amortization

8.8m15.6m

Inventories

(902.0k)(1.4m)

Cash From Operating Activities

(69.7m)(85.7m)

Purchases of PP&E

(12.3m)(10.6m)

Cash From Investing Activities

(39.5m)(45.8m)

Long-term Borrowings

(1.1m)(1.3m)

Cash From Financing Activities

227.7m4.9m

Net Change in Cash

118.5m(126.5m)

Interest Paid

(867.0k)(1.0m)

Income Taxes Paid

(10.0k)(19.0k)

BioNTech Ratios

EURFY, 2017

Debt/Equity

-1.1 x

Debt/Assets

0.1 x

Financial Leverage

-7.8 x

BioNTech Operating Metrics

Oct, 2019

Drugs in Development

20

Patents (US)

45

Phase I Trials Products

8

Phase II Trials Products

1

Pre-Clinical Phase Products

11

Scientific Collaborations

7

Trademarks (US)

8

BioNTech Employee Rating

3.619 votes
Culture & Values
3
Work/Life Balance
3.2
Senior Management
2.4
Salary & Benefits
2.4
Career Opportunities
2.5
Source